GlassScriptPhysician profile
Brooke Johnson
NPI 1932531316
$2,155.75
in general payments reported to CMS, 2019-2025
29 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $376 · 2023: $318 · 2024: $456 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.59 | 2023-2025 | |
| Novo Nordisk INC | $211.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $201.65 | 2021-2025 | Breztri |
| Amgen INC. | $181.80 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $169.19 | 2021-2025 | Jardiance, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.61 | 2021-2023 | Glyxambi, Synjardy, Tradjenta |
| Dexcom, INC. | $134.27 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $101.99 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $94.88 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $82.55 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Alkermes, INC. | $57.97 | 2022-2025 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.97 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $41.89 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $40.92 | 2021 | |
| Sanofi Pasteur INC. | $40.58 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.71 | 2023 | |
| Exact Sciences Corporation | $31.48 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $31.03 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $29.68 | 2022-2023 | Eliquis |
| Orexo US, INC. | $20.64 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.23 | 2024 | Gvoke Hypopen |
| Indivior INC. | $17.14 | 2025 | Sublocade |
| Medtronic, INC. | $16.34 | 2023 | Minimed 780g |
| Lundbeck LLC | $15.10 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $13.78 | 2021 | |
| Gilead Sciences, INC. | $13.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.84 | 2022 | |
| Merck Sharp & Dohme LLC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.